Home » Media Center » News » Gornitzky represented the underwriters in UroGen Pharma’s USD 123.6 million underwritten follow-on public offering on Nasdaq.

June 23, 2024

Gornitzky represented the underwriters in UroGen Pharma’s USD 123.6 million underwritten follow-on public offering on Nasdaq.

PDF

Gornitzky represented the underwriters, led by TD Cowen and Guggenheim Securities, in UroGen Pharma Ltd.’s USD 123.6 million underwritten follow-on public offering of shares and pre-funded warrants on Nasdaq.

UroGen is a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers.

TD Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering and Ladenburg Thalmann acted as co-manager for the offering.

Gornitzky represented the underwriters in UroGen Pharma’s USD 123.6 million underwritten follow-on public offering on Nasdaq.

KEY CONTACTS

Chaim Friedland

Ari Fried

Nir Knoll

Dr. Assaf Prussak

Rebecca Greenberg

RELATED PRACTICES

RELATED NEWS & PUBLICATIONS

Precedent-Setting Decision: Development Improvement Plans Within 100 Meters of the Shoreline

The Importance of Incoterms in International Trade

The war has had a major impact on foreign investments

Success in the Appeals Committee

Ronit Rozenstein-Barel delivers Lecture at the 2024 Energy and Business Conference

Yaron Elhawi Appointed as Debt Settlement Administrator for Kalit Sitbon Ltd.

Nona Lerner Wins the Client Choice Award in Arbitration

New EU Design Legislation: Modernizing Protection for the Digital Era

New Proposed Legislative Tax Reform regarding Corporate Reorganizations

Our Impact

Aviram Handel – Lecture at the Conference of the Court Administration for Legal Assistants at the Tel Aviv District Court